Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polo-like kinase 4 (Plk4) potentiates anoikis-resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotype.

Cell death & disease - 16 Feb 2023

Fonseca Irina, Horta Cíntia, Ribeiro Ana Sofia, Sousa Barbara, Marteil Gaëlle, Bettencourt-Dias Mónica, Paredes Joana

Abstract excerpt

Polo-like kinase 4 (Plk4), the major regulator of centriole biogenesis, has emerged as a putative therapeutic target in cancer due to its abnormal expression in human carcinomas, leading to centrosome number deregulation, mitotic defects and chromosomal instability. Moreover, Plk4 deregulation promotes tumor growth and metastasis in mouse models and is significantly associated with poor patient prognosis. Here,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Epithelial Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Phenotype

Share to Protein Serine-Threonine Kinases

Share to Tumor Microenvironment

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 36797240
DOI: 10.1038/s41419-023-05618-1
PMCID: PMC9935921

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polo-like kinase 4 (Plk4) potentiates anoikis-resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotype.PMID 36797240Read ↗

Polo-like kinase 4 (Plk4) potentiates <i>anoikis</i> -resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotypeSemantic proximity Read ↗

Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer ManagementSemantic proximity Read ↗

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Semantic proximity Read ↗

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapySemantic proximity Read ↗

The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor MetastasisSemantic proximity Read ↗

Plk1 overexpression induces chromosomal instability and suppresses tumor developmentSemantic proximity Read ↗

PLK4: a link between centriole biogenesis and cancerSemantic proximity Read ↗

Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian CancerSemantic proximity Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

Polo-like kinase 4 mediates epithelial–mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathwaySemantic proximity Read ↗

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.